Why the study?
What are the current statin prescribing patterns and potential cost savings from generic statins among hypertensive patients in Nigeria?
Observational (n=228)
No
What are the current statin prescribing patterns and potential cost savings from generic statins among hypertensive patients in Nigeria?
Increased prescribing of generic statins in Nigerian hypertensive patients could yield substantial cost savings.
Answers are grounded in this paper and cite their sources.
Potential cost savings from greater generic statin use in Nigerian hypertensives; leaves open whether targeted policies improve access or outcomes.
BACKGROUND: Statins reduce cardiovascular risk, especially in patients with hypertension due to their concomitant blood pressure reducing effects. Prescribing generic statins minimizes cost and improves access. AIMS: Ascertain current prescribing of statins in Nigeria and potential savings from the increased use of generic statins. METHODS: Prospective study involving hypertensive patients attending University College Hospital (Ibadan, Nigeria). RESULTS: In total, 228 hypertensive patients received statins. Atorvastatin was the most prescribed statin, followed by simvastatin, rosuvastatin and finally fluvastatin. Prescribed doses were less than one defined daily dose in the majority, with high use of originators. Average monthly potential savings from increased prescribing of generic statins was US$2635 for atorvastatin and US$10,578 for rosuvastatin. CONCLUSION: A shift toward increased prescribing generic statins is recommended to minimize costs.
No takes yet. Share an insight, caveat, or question.
Akunne et al. (2016) conducted an observational in Hypertension with hypercholesterolemia (n=228). Statin prescribing patterns (generic vs originator) was evaluated on Current prescribing of statins (originator vs generic) and prescribed doses compared to defined daily doses (DDD).
Synapse has enriched 10 related papers. Consider them for comparative context: